Abstract
Importance Heroin addiction is rampant and persistent, with devastating consequences to the public health, necessitating further study into the neurobiological mechanisms of drug cue-reactivity and craving-reducing interventions (e.g., reappraisal and savoring).
Objective To document cortico-striatal reactivity during passive viewing, reappraisal, and savoring, as predictors of heroin craving in individuals with heroin use disorder (iHUD) vs. controls.
Design A cross-sectional study (11/2020-09/2021), with a novel fMRI task in iHUD vs. controls.
Setting iHUD and controls were recruited from treatment facilities and surrounding neighborhoods, respectively.
Participants iHUD (N=32) [40.3±8.8 years; 7 (21.9%) women] and age-/sex-matched controls (N=21) [40.6±10.8 years; 8 (38%) women].
Main Outcomes and Measures Between-group blood-oxygen-level-dependent signal differences during cue-reactivity/reappraisal/savoring and their direct contrast (reappraisal vs. savoring), and correlations with drug craving in iHUD.
Results Drug cue-reactivity (look drug>neutral) revealed higher nucleus accumbens and ventromedial prefrontal cortical activity in iHUD vs. controls (Z>3.1, p<.05), the latter positively correlated with post-task drug cravings (r2=.47, p<.001). In contrast, controls showed higher dorsolateral prefrontal cortex (dlPFC) and inferior frontal gyrus (IFG) reactivity to food cues (>drug; Z>3.1, p<.05; with the opposite pattern for the iHUD). Both drug-reappraisal and food-savoring (vs. respective passive viewing) showed increased activity in the IFG and supplementary motor area in all participants; the higher the dlPFC/IFG drug reappraisal in iHUD, the lower the post-MRI drug cue-induced craving (Z>3.1, p<.05). A direct comparison (drug-reappraisal vs. food-savoring) revealed higher drug-reappraisal in the ventral caudate and PFC regions in the iHUD (Z>3.1, p<.05), as predicted in the striatum by pre-task drug cravings (Z>2.57, p<.05); in controls, these areas showed instead higher food-savoring (Z>3.1, p<.05).
Conclusions and Relevance We demonstrate upregulated cortico-striatal activity during drug-cue exposure (while passively looking or reappraising) and impaired reactivity during processing (looking or savoring) of non-drug rewards in heroin addiction. These results bolster the impaired response inhibition and salience attribution model of drug addiction, previously supported mostly by results in stimulant addiction. Normalizing cortico-striatal function by reducing drug cue-reactivity (e.g., reappraising drug cues) and enhancing natural reward valuation (e.g., savoring food stimuli) may inform therapeutic mechanisms for reducing drug craving/seeking in heroin addiction.
Question What are the cortico-striatal brain regions driving reactivity to and reappraisal of drug vs. savoring food cues in individuals with heroin use disorder (iHUD); do these activations contribute to self-reported drug cravings?
Findings In this cross-sectional study, and compared to matched healthy control subjects, iHUD exhibited cortico-striatal reward and self-control regional hyperactivations to drug cues during both passive viewing of pictures and their reappraisal as compared to savoring of alternative reward (images of food); and these activations correlated with drug cravings.
Meaning We identified drug-cue biased processing in cortico-striatal regions in iHUD, providing potential therapeutic biomarkers for neuromodulation and cognitive training in reducing hyper-responsiveness to drug cues and enhancing responses to alternative natural rewards.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by R01DA048094 to EG and R01AT010627 to RZG.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Icahn School of Medicine at Mount Sinai institutional review board approved study procedures and all participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosures: The authors declare no competing financial interests.
Funding/Support: This work was supported by R01DA048094 to EG and R01AT010627 to RZG.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
